Ozmosi | Ethionamide Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Ethionamide

Alternative Names: ethionamide, trecator
Clinical Status: Inactive
Latest Update: 2025-10-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Cell Wall Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular, Intravenous, Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Brazil | Chile | China | Colombia | Greece | India | Malaysia | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | South Africa | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: TASK Applied Science
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ethionamide

Countries in Clinic: South Africa

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Tuberculosis|Tuberculosis, Pulmonary

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06748937

ENABLE

P2

Recruiting

Tuberculosis

2026-03-30

2025-03-08

NCT05473195

BETO

P2

Completed

Tuberculosis, Pulmonary

2024-04-16

2025-08-22

Patient Enrollment|Primary Endpoints

Recent News Events

Date

Type

Title